Scinai Immunotherapeutics Ltd. (SCNI) Stock Score, Valuation & Financial Research
Scinai Immunotherapeutics Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 19/100.
Quick answer for SCNI
Scinai Immunotherapeutics Ltd. currently has a Wall Street Score of 19/100. The stored market price is $1.56. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Scinai Immunotherapeutics Ltd. does
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
SCNI financial snapshot
- Wall Street Score:
- 19/100
- Current price:
- $1.56
- Market capitalization:
- $806K
- Revenue:
- $1.5M
- Net income:
- $-2.6M
- Free cash flow:
- $-6.1M
- Cash:
- $2.9M
- Total debt:
- $3.6M
- EPS:
- -62161.60
- Financial score:
- 25/100
- Valuation score:
- 0/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-6.1M, showing cash burn in the current stored period.
- The balance sheet shows $2.9M of cash versus $3.6M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: SCNI increased 0.1 points because overall fundamentals improved.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
Questions worth answering for SCNI
These questions are derived from the company's current stored financial and score data so the page adds company-specific research context instead of treating the headline score as a stand-alone conclusion.
- Can SCNI maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- How long can SCNI fund negative free cash flow using its current cash position before it may need more debt or new shares?
- Does SCNI's balance between cash and debt leave enough flexibility if business conditions weaken?
- What specifically needs to improve for SCNI to reach sustainable profitability?
- What future growth or profitability would be needed to justify SCNI's current valuation?
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-19.
Research-input completeness: 82% of the scoring inputs required for this public page are currently available.
How to research SCNI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.